211915-06-9 | Dabigatran etexilate

Packsize	Purity	Availability	Price	Discounted Price
50mg	98%	in stock	$6.00	$4.00
100mg	98%	in stock	$6.00	$4.00
250mg	98%	in stock	$8.00	$5.00
1g	98%	in stock	$12.00	$8.00
5g	98%	in stock	$33.00	$23.00
25g	98%	in stock	$110.00	$77.00

Description

• Catalog Number: AD24793
• Chemical Name: Dabigatran etexilate
• CAS Number: 211915-06-9
• Molecular Formula: C34H41N7O5
• Molecular Weight: 627.7332
• MDL Number: MFCD22422841
• SMILES: CCCCCCOC(=O)N/N=C/c1ccc(cc1)NCc1nc2c(n1C)ccc(c2)C(=O)N(c1ccccn1)CCC(=O)OCC

Computed Properties

• Complexity: 1000
• Covalently-Bonded Unit Count: 1
• Defined Bond Stereocenter Count: 1
• Heavy Atom Count: 46
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 17
• XLogP3: 5.7

Literature

• Overview of the new oral anticoagulants: opportunities and challenges.

  Arteriosclerosis, thrombosis, and vascular biology 20150501

• Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice.

  The Journal of pharmacology and experimental therapeutics 20141101

• A specific antidote for dabigatran: functional and structural characterization.

  Blood 20130502

• New oral anticoagulants: comparative pharmacology with vitamin K antagonists.

  Clinical pharmacokinetics 20130201

• The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.

  Thrombosis research 20121101

• Use of direct thrombin inhibitor for treatment of cerebral venous thrombosis.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20121101

• Intravenous thrombolysis in a stroke patient taking dabigatran.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20121101

• Dabigatran and left atrial appendage thrombus.

  Journal of thrombosis and thrombolysis 20121101

• Acute ischemic stroke treated with intravenous tissue plasminogen activator in a patient taking dabigatran with radiographic evidence of recanalization.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20121101

• The effects of direct thrombin inhibition with dabigatran on plaque formation and endothelial function in apolipoprotein E-deficient mice.

  The Journal of pharmacology and experimental therapeutics 20121101

• Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.

  Thrombosis research 20121101

• Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.

  Journal of thrombosis and thrombolysis 20121101

• Hemorrhagic complications associated with dabigatran use.

  Clinical toxicology (Philadelphia, Pa.) 20121101

• Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.

  British journal of haematology 20121101

• Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.

  Thrombosis and haemostasis 20121101

• Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

  Thrombosis and haemostasis 20121101

• [Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].

  Therapeutische Umschau. Revue therapeutique 20121101

• [Clinical pharmacological aspects of new oral anticoagulants].

  Therapeutische Umschau. Revue therapeutique 20121101

• Mechanical valve thrombosis with dabigatran.

  Journal of the American College of Cardiology 20121023

• Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options.

  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001

• Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.

  PharmacoEconomics 20121001

• Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.

  QJM : monthly journal of the Association of Physicians 20121001

• Determination of the anti-F10a or anti-F2a generation action of rivaroxaban or dabigatran.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20121001

• A comparison of bleeding complications post-ablation between warfarin and dabigatran.

  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001

• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.

  Thrombosis and haemostasis 20121001

• Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.

  Thrombosis and haemostasis 20121001

• Dabigatran: laboratory monitoring.

  Pathology 20121001

• New anticoagulants for stroke prophylaxis in atrial fibrillation: assessing the impact on medication adherence.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20121001

• Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20121001

• What did we learn from new oral anticoagulant treatment?

  Thrombosis research 20121001

• Antithrombotic treatment of atrial fibrillation: new insights.

  Thrombosis research 20121001

• Dabigatran in clinical practice.

  Clinical therapeutics 20121001

• The new oral anticoagulants and the future of haemostasis laboratory testing.

  Biochemia medica 20121001

• [Dabigatran etexilate in clinical practice for prevention of thromboembolic events in patients with atrial fibrillation].

  Vnitrni lekarstvi 20121001

• The safety risks of innovation: the FDA's Expedited Drug Development Pathway.

  JAMA 20120905

• Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation.

  Journal of clinical pharmacology 20120901

• Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

  British journal of clinical pharmacology 20120901

• Stroke prophylaxis with warfarin or dabigatran for patients with non-valvular atrial fibrillation-cost analysis.

  Age and ageing 20120901

• Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20120901

• Dabigatran: comparison to warfarin, pathway to approval, and practical guidelines for use.

  Journal of cardiovascular pharmacology and therapeutics 20120901

• Treatment of venous thromboembolism with dabigatran.

  Current opinion in pulmonary medicine 20120901

• Evaluation of the acute coronary syndrome safety profile of dabigatran etexilate in patients undergoing major orthopedic surgery: findings from four Phase 3 trials.

  Thrombosis research 20120901

• Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.

  Coronary artery disease 20120901

• Dabigatran etexilate: a pharmacoeconomic review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

  PharmacoEconomics 20120901

• The management of antithrombotic medication in skin surgery.

  Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 20120901

• Spontaneous gross haematuria during dabigatran therapy for secondary stroke prevention.

  Thrombosis and haemostasis 20120901

• An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

  Thrombosis and haemostasis 20120901

• Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.

  Thrombosis and haemostasis 20120901

• Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

  Journal of thrombosis and haemostasis : JTH 20120901

• Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.

  Journal of thrombosis and haemostasis : JTH 20120901

• Safe use of hemodialysis for dabigatran removal before cardiac surgery.

  The Annals of pharmacotherapy 20120901

• The novel oral anticoagulants: an update for the interventional radiologist.

  AJR. American journal of roentgenology 20120901

• [The new anticoagulants - their role in secondary prevention of thromboembolism after stroke].

  Therapeutische Umschau. Revue therapeutique 20120901

• National trends in oral anticoagulant use in the United States, 2007 to 2011.

  Circulation. Cardiovascular quality and outcomes 20120901

• The promise of novel direct oral anticoagulants.

  Best practice & research. Clinical haematology 20120901

• Perioperative management of dabigatran: the Nelson experience to date.

  The New Zealand medical journal 20120824

• Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

  Journal of the American College of Cardiology 20120821

• Danger ahead: watch out for indirect comparisons!

  Journal of the American College of Cardiology 20120821

• Thrombosis of a mechanical heart valve despite dabigatran.

  Annals of internal medicine 20120821

• A new era of antithrombotic therapy in patients with atrial fibrillation.

  The American journal of the medical sciences 20120801

• Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.

  Thrombosis research 20120801

• Acute stroke management in patients taking dabigatran.

  CNS neuroscience & therapeutics 20120801

• Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

  The American journal of cardiology 20120801

• The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.

  The American journal of medicine 20120801

• Spontaneous ascending aortic intramural haematoma in a patient on dabigatran.

  Interactive cardiovascular and thoracic surgery 20120801

• Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.

  Thrombosis and haemostasis 20120801

• Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.

  Thrombosis and haemostasis 20120801

• Fatal gastrointestinal hemorrhage after a single dose of dabigatran.

  Clinical toxicology (Philadelphia, Pa.) 20120801

• Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

  International angiology : a journal of the International Union of Angiology 20120801

• Complications of anticoagulation.

  Disease-a-month : DM 20120801

• [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].

  Zeitschrift fur Gerontologie und Geriatrie 20120801

• Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.

  Minerva cardioangiologica 20120801

• Atraumatic acute carpal tunnel syndrome in a patient taking dabigatran.

  Orthopedics 20120801

• Periprocedural anticoagulant management.

  Hospital practice (1995) 20120801

• The new oral anticoagulants: a challenge for hospital formularies.

  Hospital practice (1995) 20120801

• Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.

  Circulation 20120717

• Anticoagulation, novel agents, and procedures: can we pardon the interruption?

  Circulation 20120717

• Epistaxis associated with dabigatran in an elderly patient with reduced creatinine clearance.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120715

• Dabigatran: uncharted waters and potential harms.

  Annals of internal medicine 20120703

• New oral anticoagulants for atrial fibrillation.

  Circulation 20120703

• Thrombotic events after discontinuing dabigatran: rebound or resumption?

  BMJ (Clinical research ed.) 20120703

• Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding.

  Thrombosis and haemostasis 20120701

• Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.

  Circulation. Cardiovascular quality and outcomes 20120701

• Evaluating and assessing dabigatran drug interactions.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20120701

• Dabigatran in recurrent deep vein thrombosis: when one-size does not fit all.

  The Israel Medical Association journal : IMAJ 20120701

• Faculty of Consulting Physicians of South Africa (FCPSA): saving brain with dabigatran.

  Cardiovascular journal of Africa 20120701

• Dabigatran: rational dose individualisation and monitoring guidance is needed.

  The New Zealand medical journal 20120629

• Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran).

  Spine 20120615

• Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial.

  Expert opinion on pharmacotherapy 20120601

• New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation.

  Journal of internal medicine 20120601

• Anti-stroke prophylaxis--the ethics of collateral damage.

  Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20120601

• Dabigatran: a new chapter in anticoagulation.

  Cardiovascular & hematological agents in medicinal chemistry 20120601

• Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.

  Stroke 20120601

• Long-term benefits of preventing venous thromboembolic events.

  Current medical research and opinion 20120601

• Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?

  Expert opinion on pharmacotherapy 20120601

• Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.

  Journal of investigative surgery : the official journal of the Academy of Surgical Research 20120601

• Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation.

  Critical pathways in cardiology 20120601

• An audience with... Gregory Lip. Interview by Asher Mullard.

  Nature reviews. Drug discovery 20120601

• Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients.

  The Annals of pharmacotherapy 20120601

• An anticoagulation option for nonvalvular atrial fibrillation.

  The Journal of family practice 20120601

• Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

  Advances in therapy 20120601

• Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20120601

• A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).

  American heart journal 20120601

• New anticoagulant fights for credibility.

  Managed care (Langhorne, Pa.) 20120601

• Novel oral anticoagulants for stroke prevention in atrial fibrillation.

  European heart journal 20120601

• [Series: Clinical study from Japan and its reflections RE-LY trial].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20120510

• Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

  Drugs 20120507

• Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.

  European journal of clinical pharmacology 20120501

• Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation.

  Journal of thrombosis and haemostasis : JTH 20120501

• Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.

  Journal of neurosurgery 20120501

• Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.

  Thrombosis and haemostasis 20120501

• Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.

  Annals of neurology 20120501

• Hemopericardium in a patient treated with dabigatran etexilate.

  Pharmacotherapy 20120501

• Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.

  Vascular and endovascular surgery 20120501

• Novel oral anticoagulants--key messages for the angiologist.

  VASA. Zeitschrift fur Gefasskrankheiten 20120501

• Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management.

  Wiener klinische Wochenschrift 20120501

• New oral anticoagulants: will they replace warfarin?

  Oral surgery, oral medicine, oral pathology and oral radiology 20120501

• Oral anticoagulants for atrial fibrillation: Which one to choose?

  Advance for NPs & PAs 20120501

• Newer oral anticoagulant agents: a new era in medicine.

  Current cardiology reviews 20120501

• Prescribing trends for dabigatran etexilate in primary care.

  Irish medical journal 20120501

• [The monitoring of application of dabigatran as a remedy of prevention of thromboembolic complications after hip joint arthroplasty].

  Klinicheskaia laboratornaia diagnostika 20120501

• Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).

  Journal of medicinal chemistry 20120426

• Avoiding adverse events with dabigatran by careful selection of eligible patients.

  The Medical journal of Australia 20120416

• New medicines - urgent need to assess outcomes in special groups.

  The Medical journal of Australia 20120416

• Endovascular therapy after stroke in a patient treated with dabigatran.

  The Medical journal of Australia 20120416

• Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].

  International orthopaedics 20120401

• Interpretation of point-of-care INR results in patients treated with dabigatran.

  The American journal of medicine 20120401

• Clinical challenges in a patient with dabigatran-induced fatal hemorrhage.

  The American journal of geriatric pharmacotherapy 20120401

• A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery.

  Thrombosis and haemostasis 20120401

• Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation.

  Heart (British Cardiac Society) 20120401

• Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.

  American journal of clinical pathology 20120401

• Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

  Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 20120401

• Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.

  Clinical therapeutics 20120401

• Thromboembolic prophylaxis in orthopedic surgery using dabigatran: an oral direct thrombin inhibitor.

  Expert review of cardiovascular therapy 20120401

• Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment.

  The Annals of pharmacotherapy 20120401

• Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients.

  Oral surgery, oral medicine, oral pathology and oral radiology 20120401

• Anticoagulation for atrial fibrillation ablation: what is the optimal strategy?

  Journal of the American College of Cardiology 20120327

• Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry.

  Journal of the American College of Cardiology 20120327

• Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants.

  Circulation 20120327

• [Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].

  MMW Fortschritte der Medizin 20120322

• Important data after drug approval: comment on 'Dabigatran association with higher risk of acute coronary events'.

  Archives of internal medicine 20120312

• Dabigatran: do we have sufficient data?: comment on 'Dabigatran association with higher risk of acute coronary events'.

  Archives of internal medicine 20120312

• Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

  Archives of internal medicine 20120312

• Dabigitran and the radiology department.

  Irish journal of medical science 20120301

• The use of dabigatran immediately after atrial fibrillation ablation.

  Journal of cardiovascular electrophysiology 20120301

• What's a mother to do?

  Journal of cardiovascular electrophysiology 20120301

• Dabigatran etexilate: what do hospitalists need to know?

  Journal of hospital medicine 20120301

• Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

  Thrombosis and haemostasis 20120301

• Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20120301

• Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

  Stroke 20120301

• What's the 'go to' anticoagulant for stroke prevention in atrial fibrillation?

  Thrombosis and haemostasis 20120301

• New directions in anticoagulation.

  The American journal of medicine 20120301

• Dabigatran (Pradaxa).

  AJNR. American journal of neuroradiology 20120301

• A new generation of oral direct anticoagulants.

  Arteriosclerosis, thrombosis, and vascular biology 20120301

• [Controversy. Dabigatran in the preventive treatment of embolic stroke: arguments in favour of its utilisation as a first-choice drug].

  Revista de neurologia 20120301

• [Controversy. Dabigatran in the preventive treatment of embolic stroke: arguments against its utilisation as a first-choice drug].

  Revista de neurologia 20120301

• Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.

  The neurologist 20120301

• Bleeding risk with dabigatran in the frail elderly.

  The New England journal of medicine 20120301

• Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.

  Blood 20120301

• [Clinical studies, the interests and limits of using dabigatran in atrial fibrillation].

  Journal de pharmacie de Belgique 20120301

• [Pharmacological sheet. Dabigatran, oral administration (Pradaxa)].

  Journal de pharmacie de Belgique 20120301

• [Prevention of cardioembolic stroke].

  Neurologia (Barcelona, Spain) 20120301

• [Dabigatran: a new therapeutic alternative in the prevention of stroke].

  Neurologia (Barcelona, Spain) 20120301

• Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.

  Journal of the American College of Cardiology 20120227

• Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

  Circulation 20120207

• Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies.

  Blood 20120202

• Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment.

  Neurocritical care 20120201

• Rivaroxaban for the prevention and treatment of venous thromboembolism.

  Fundamental & clinical pharmacology 20120201

• Preventing cardioembolic stroke in atrial fibrillation with dabigatran.

  Current neurology and neuroscience reports 20120201

• Lack of an antagonist to reverse the action of dabigatran.

  QJM : monthly journal of the Association of Physicians 20120201

• Promise of factor Xa inhibition in atrial fibrillation.

  Current cardiology reports 20120201

• First cascade Mitsunobu reactions for the synthesis of 2-benzoxazole-N-phenyl and 2-benzimidazole-N-phenyl derivatives.

  Molecular diversity 20120201

• Stroke prevention in atrial fibrillation: do we still need warfarin?

  Current opinion in neurology 20120201

• Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal.

  PharmacoEconomics 20120201

• Pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects after oral administration of dabigatran etexilate.

  Thrombosis and haemostasis 20120201

• A new approach with anticoagulant development: tailoring anticoagulant therapy with dabigatran etexilate according to patient risk.

  Expert opinion on pharmacotherapy 20120201

• Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.

  Current medical research and opinion 20120201

• Using anticoagulants to steer clear of clots.

  Nursing 20120201

• Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.

  Neurosurgery 20120201

• The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?

  International journal of stroke : official journal of the International Stroke Society 20120201

• Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease.

  Expert review of neurotherapeutics 20120201

• The oral thrombin inhibitor dabigatran: strengths and weaknesses.

  Seminars in thrombosis and hemostasis 20120201

• Determination of dabigatran in human plasma samples.

  Seminars in thrombosis and hemostasis 20120201

• Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  Chest 20120201

• Warfarin versus dabigatran: comparing the old with the new.

  The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20120201

• Dabigatran product familiarisation programmes: who benefits, who shouldn't get it?

  Internal medicine journal 20120201

• Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.

  Prescrire international 20120201

• Anticoagulant loses its lustre.

  Lancet (London, England) 20120128

• Switching patients from warfarin to dabigatran therapy: to RE-LY or not to rely.

  International journal of cardiology 20120126

• UPLC MS/MS assay for routine quantification of dabigatran - a direct thrombin inhibitor - in human plasma.

  Journal of pharmaceutical and biomedical analysis 20120125

• [Expanded arsenal in atrial fibrillation: bye-bye marcumar?].

  MMW Fortschritte der Medizin 20120119

• Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20120101

• Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran.

  Heart, lung & circulation 20120101

• Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.

  Journal of clinical pharmacology 20120101

• Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation.

  Journal of internal medicine 20120101

• Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.

  Acta neurochirurgica 20120101

• Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke.

  Journal of thrombosis and thrombolysis 20120101

• Concerns about studies investigating new anticoagulant drugs for stroke prevention in atrial fibrillation.

  Journal of neurology 20120101

• [Anticoagulation in atrial fibrillation: a new era has begun].

  Hamostaseologie 20120101

• Using dabigatran in patients with stroke: a practical guide for clinicians.

  Stroke 20120101

• Dabigatran use in a postoperative coronary artery bypass surgery patient with nonvalvular atrial fibrillation and heparin-PF4 antibodies.

  The Annals of pharmacotherapy 20120101

• Dabigatran in clinical practice for atrial fibrillation with special reference to activated partial thromboplastin time.

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?

  Cardiology journal 20120101

• [Pharmacoeconomic analysis of dabigatran etexilate effectiveness in patients with nonvalvular atrial fibrillation].

  Kardiologiia 20120101

• New antiplatelet and anticoagulant drugs.

  General dentistry 20120101

• Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.

  Postgraduate medicine 20120101

• New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.

  Vascular health and risk management 20120101

• I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?

  DukeMedicine healthnews 20120101

• Monitoring of the effects of new-generation oral anticoagulants – what does it mean? – .

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• Improving prevention and treatment of venous thromboembolism: clinical trial results.

  Journal of medical economics 20120101

• Exfoliative esophagitis and esophageal ulcer induced by dabigatran.

  Endoscopy 20120101

• Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.

  Journal of medical economics 20120101

• [Update on current care guidelines: atrial fibrillation].

  Duodecim; laaketieteellinen aikakauskirja 20120101

• Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.

  Journal of medical economics 20120101

• Hitting back HIT.

  Annals of cardiac anaesthesia 20120101

• Economic evaluation of dabigatran etexilate for the primary prevention of venous tromboembolic events following major orthopedic surgery in the Netherlands.

  Journal of medical economics 20120101

• [New antithrombotic drugs].

  Duodecim; laaketieteellinen aikakauskirja 20120101

• [Dabigatran and emergency operation on a peritonitis patient].

  Duodecim; laaketieteellinen aikakauskirja 20120101

• Dabigatran: a new anticoagulant for stroke prevention in patients with atrial fibrillation.

  Missouri medicine 20120101

• Newer anticoagulants for the prevention of venous thromboembolism.

  The National medical journal of India 20120101

• Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

  BMJ (Clinical research ed.) 20120101

• Dabigatran for stroke prevention in atrial fibrillation.

  Hamostaseologie 20120101

• Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.

  PloS one 20120101

• Pharmacokinetic and clinical implications of dabigatran use in severe renal impairment for stroke prevention in nonvalvular atrial fibrillation.

  The Annals of pharmacotherapy 20120101

• Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation.

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• Can dabigatran be an alternative periprocedural anticoagulation for atrial fibrillation ablation?

  Circulation journal : official journal of the Japanese Circulation Society 20120101

• Hemopericardium and cardiac tamponade associated with dabigatran use.

  The Annals of pharmacotherapy 20120101

• [New anticoagulants: dabigatran, rivaroxaban and apixaban].

  Gaceta medica de Mexico 20120101

• Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges.

  Current medicinal chemistry 20120101

• [Comparison of three methods of antithrombotic therapy in elderly patients with nonvalvular atrial fibrillation].

  Kardiologiia 20120101

• Agranulocytosis immediately after oral administration of cibenzoline and dabigatran in a patient with paroxysmal atrial fibrillation.

  Internal medicine (Tokyo, Japan) 20120101

• No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.

  PloS one 20120101

• Diffuse alveolar hemorrhage associated with dabigatran.

  Internal medicine (Tokyo, Japan) 20120101

• [New oral anticoagulants for atrial fibrillation: a neurologist's view].

  Nederlands tijdschrift voor geneeskunde 20120101

• The ps in therapeutics.

  International journal of pharmaceutical compounding 20120101

• [Therapeutic approach to the bleeding in association with 'old' and 'new' anticoagulants].

  Vnitrni lekarstvi 20120101

• [Anticoagulant therapy in connection with cardioversion in patients with atrial fibrillation].

  Kardiologiia 20120101

• Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests.

  Clinical chemistry and laboratory medicine 20120101

• [Dabigatran therapy--perioperative management and interpretation of coagulation tests].

  Hamostaseologie 20120101

• Bleeding with dabigatran (Pradaxa).

  The Medical letter on drugs and therapeutics 20111212

• Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty.

  Archives of orthopaedic and trauma surgery 20111201

• Dabigatran in atrial fibrillation: pharmacology and clinical trials.

  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20111201

• New anticoagulants: moving on from scientific results to clinical implementation.

  Annals of medicine 20111201

• Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant.

  Journal of medical toxicology : official journal of the American College of Medical Toxicology 20111201

• [New anticoagulants: 'efficacy and safety' or 'efficacy or safety'].

  Journal des maladies vasculaires 20111201

• Advances in anticoagulation: focus on dabigatran, an oral direct thrombin inhibitor.

  Journal of cardiothoracic and vascular anesthesia 20111201

• Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

  Stroke 20111201

• Inhibition of staphylothrombin by dabigatran reduces Staphylococcus aureus virulence.

  Journal of thrombosis and haemostasis : JTH 20111201

• Dabigatran: a new oral anticoagulant.

  Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses 20111201

• Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies.

  Pharmacotherapy 20111201

• Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.

  Pharmacotherapy 20111201

• [Pharmacologic heterogeneity of new anticoagulants].

  Journal des maladies vasculaires 20111201

• [New treatments for venous thromboembolic disease].

  Journal des maladies vasculaires 20111201

• Dabigatran versus warfarin for patients with non-valvular atrial fibrillation: is the patient the winner?

  Australian nursing journal (July 1993) 20111201

• Acutely injured patients on dabigatran.

  The New England journal of medicine 20111124

• Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

  Annals of internal medicine 20111115

• Learning the respective roles of warfarin and dabigatran to prevent stroke in patients with nonvalvular atrial fibrillation.

  Annals of internal medicine 20111115

• Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.

  European heart journal 20111101

• Redemption by RE-DEEM?

  European heart journal 20111101

• Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).

  Thrombosis and haemostasis 20111101

• Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial.

  Journal of thrombosis and haemostasis : JTH 20111101

• A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.

  Stroke 20111101

• [New anticoagulants. Characteristics, monitoring and management of bleeding].

  Medizinische Klinik, Intensivmedizin und Notfallmedizin 20111101

• [Expectation to and problems of thrombin inhibitor].

  Rinsho shinkeigaku = Clinical neurology 20111101

• [New anticoagulants].

  La Revue du praticien 20111101

• Anticoagulation with the oral direct thrombin inhibitor dabigatran does not enlarge hematoma volume in experimental intracerebral hemorrhage.

  Circulation 20111011

• Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

  Circulation 20111004

• Reversal of new oral anticoagulants.

  Circulation 20111004

• Direct thrombin inhibitors.

  British journal of clinical pharmacology 20111001

• Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux.

  British journal of clinical pharmacology 20111001

• Update on the management of atrial fibrillation: anticoagulation and medical therapy.

  Current cardiology reports 20111001

• New anticoagulants: how to deal with treatment failure and bleeding complications.

  British journal of clinical pharmacology 20111001

• Anticoagulating obese patients in the modern era.

  British journal of haematology 20111001

• Drug-induced exanthem following dabigatran.

  The Annals of pharmacotherapy 20111001

• Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.

  Orthopedics 20111001

• Dabigatran: will it change clinical practice?

  Cleveland Clinic journal of medicine 20111001

• Should dabigatran replace warfarin for stroke prevention in AF?

  Drug and therapeutics bulletin 20111001

• The new oral anticoagulants.

  Clinical medicine (London, England) 20111001

• Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.

  Hospital practice (1995) 20111001

• [Interpretation of hemostatic and fibrinolytic markers].

  Rinsho byori. The Japanese journal of clinical pathology 20111001

• [Atrial fibrillation: what the GP needs to know].

  MMW Fortschritte der Medizin 20110922

• A new era for anticoagulation in atrial fibrillation.

  The New England journal of medicine 20110915

• New options in anticoagulation for atrial fibrillation.

  The New England journal of medicine 20110908

• Dabigatran falsely elevates point of care international normalized ratio results.

  The American journal of medicine 20110901

• Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.

  Journal of thrombosis and haemostasis : JTH 20110901

• Update on anti-coagulation in atrial fibrillation.

  QJM : monthly journal of the Association of Physicians 20110901

• Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.

  The Nurse practitioner 20110901

• [Thromboembolic prophylaxis 2011: is warfarin on the wane?].

  Giornale italiano di cardiologia (2006) 20110901

• Update on dabigatran for stroke prevention in atrial fibrillation.

  Connecticut medicine 20110901

• Dabigatran: a review of clinical and pharmacoeconomic evidence.

  Critical pathways in cardiology 20110901

• Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.

  Seminars in vascular surgery 20110901

• New antithrombotic drugs and European approval processes.

  Lancet (London, England) 20110820

• Dabigatran-induced rash.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110815

• Pros and cons of dabigatran.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110815

• Dabigatran etexilate: A novel oral direct thrombin inhibitor.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110815

• [The new Anticoagulants - Relevant Facts for the GP].

  Praxis 20110810

• ['Xa-tra-xa': opportunities and open questions about new anticoagulants].

  Praxis 20110810

• Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.

  European heart journal 20110801

• Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.

  Journal of thrombosis and haemostasis : JTH 20110801

• New anticoagulants for prevention of stroke in patients with atrial fibrillation.

  Journal of cardiovascular electrophysiology 20110801

• [New concepts in the therapy of atrial fibrillation].

  Deutsche medizinische Wochenschrift (1946) 20110801

• [Pharmacological and clinical profiles of the direct thrombin inhibitor dabigatran etexilate methane sulfate (Prazaxa(®)) ].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20110801

• Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.

  Hospital practice (1995) 20110801

• Dabigatran for stroke prevention in all patients with atrial fibrillation?

  Pharmacotherapy 20110801

• Dabigatran in patients with nonvalvular atrial fibrillation.

  Journal of the American College of Cardiology 20110726

• The use of dabigatran in elderly patients.

  Archives of internal medicine 20110725

• New anticoagulant drugs among elderly patients is caution necessary?: Comment on 'The use of dabigatran in elderly patients'.

  Archives of internal medicine 20110725

• Atrial fibrillation: outpatient presentation and management.

  Circulation 20110705

• Novel oral anticoagulants in development: Dabigatran, Rivaroxaban, and Apixaban.

  American journal of therapeutics 20110701

• S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy.

  Journal of thrombosis and haemostasis : JTH 20110701

• Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.

  Thrombosis and haemostasis 20110701

• Frontiers of anticoagulation therapy for atrial fibrillation.

  Journal of cardiology 20110701

• Potential inaccuracy of point-of-care INR in dabigatran-treated patients.

  The Annals of pharmacotherapy 20110701

• [New anticoagulants in the prevention and treatment of venous thromboembolism].

  Orvosi hetilap 20110619

• Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.

  Circulation 20110607

• Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.

  The Journal of thoracic and cardiovascular surgery 20110601

• Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation.

  Advances in therapy 20110601

• Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice.

  Expert opinion on pharmacotherapy 20110601

• New drugs 2011 part 2.

  Nursing 20110601

• A benefit-risk assessment of dabigatran in the prevention of venous thromboembolism in orthopaedic surgery.

  Drug safety 20110601

• Atrial fibrillation: epidemiology, prognosis and therapy.

  Minerva medica 20110601

• Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.

  International angiology : a journal of the International Union of Angiology 20110601

• [Is the era from the end of warfarin?].

  Medizinische Monatsschrift fur Pharmazeuten 20110601

• Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.

  Critical pathways in cardiology 20110601

• What are the emerging therapeutic alternatives to warfarin in stroke patients? How would the results of RE-LY benefit Pakistanis?

  JPMA. The Journal of the Pakistan Medical Association 20110601

• Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

  Circulation 20110531

• Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.

  The New England journal of medicine 20110512

• Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement.

  Thrombosis research 20110501

• Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.

  Arthritis and rheumatism 20110501

• Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective.

  Thrombosis and haemostasis 20110501

• Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.

  The Annals of pharmacotherapy 20110501

• [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

  Medecine sciences : M/S 20110501

• Ask the doctor. For several years, I have been taking warfarin because of atrial fibrillation. I recently suffered several nosebleeds, which took two days to control. The trauma of those episodes makes me want to swear off warfarin, but I am not sure what other options I have.

  Harvard health letter 20110501

• Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

  Annals of internal medicine 20110419

• Dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

  Annals of internal medicine 20110419

• [Current and future therapies for prophylaxis of thromboembolism in atrial fibrillation].

  MMW Fortschritte der Medizin 20110414

• Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.

  Thrombosis and haemostasis 20110401

• What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?

  Thrombosis and haemostasis 20110401

• New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.

  Thrombosis and haemostasis 20110401

• [Dabigatran, a new oral anticoagulant].

  Brain and nerve = Shinkei kenkyu no shinpo 20110401

• Place of dabigatran in contemporary pharmacotherapy.

  Pharmacotherapy 20110401

• Preventing postsurgical venous thromboembolism: pharmacological approaches.

  Seminars in thrombosis and hemostasis 20110401

• Differences between the varicella vaccines; using dabigatran.

  JAAPA : official journal of the American Academy of Physician Assistants 20110401

• 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  Circulation 20110315

• 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  Journal of the American College of Cardiology 20110315

• Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban.

  Expert opinion on pharmacotherapy 20110301

• 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  Heart rhythm 20110301

• [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].

  Revista clinica espanola 20110301

• Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management.

  Polskie Archiwum Medycyny Wewnetrznej 20110301

• Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.

  Expert review of cardiovascular therapy 20110301

• Anticoagulation: improve care quality or use new alternatives?

  Lancet (London, England) 20110205

• Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.

  Pharmacology & therapeutics 20110201

• Stroke prevention in the high-risk atrial fibrillation patient: Medical management.

  Current cardiology reports 20110201

• Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.

  Thrombosis and haemostasis 20110201

• Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

  Journal of clinical pharmacy and therapeutics 20110201

• [Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].

  Journal des maladies vasculaires 20110201

• Atrial fibrillation in 2010: advances in treatment and management.

  Nature reviews. Cardiology 20110201

• New anticoagulants: pharmacology and clinical studies.

  Wiener medizinische Wochenschrift (1946) 20110201

• Direct thrombin and factor Xa inhibitors in children: a quest for new anticoagulants for children.

  Wiener medizinische Wochenschrift (1946) 20110201

• Next generation anticoagulants may push warfarin to the wayside.

  Managed care (Langhorne, Pa.) 20110201

• Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?

  Hospital practice (1995) 20110201

• New drug offers warfarin alternative for atrial fibrillation. An immediate switch is right for some people, but not necessary for all.

  Harvard heart letter : from Harvard Medical School 20110201

• New oral anticoagulants and outpatient prophylaxis of venous thromboembolism.

  The American journal of managed care 20110201

• Characteristics of novel anticoagulants and potential economic implications.

  The American journal of managed care 20110201

• Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?

  Neurosurgery 20110201

• Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

  Circulation 20110118

• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.

  BMJ (Clinical research ed.) 20110118

• Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

  Annals of internal medicine 20110104

• Novel anticoagulants: new evidence for emerging drugs and their potential application in major lower limb surgery.

  Current vascular pharmacology 20110101

• Factor Xa and thrombin as targets for new oral anticoagulants.

  Thrombosis research 20110101

• Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

  Annual review of medicine 20110101

• New drugs: dabigatran etexilate mesylate, fingolimod hydrochloride, and ulipristal acetate.

  Journal of the American Pharmacists Association : JAPhA 20110101

• The difference between Tdap and DTaP; dabigatran versus warfarin.

  JAAPA : official journal of the American Academy of Physician Assistants 20110101

• Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101

• New oral anticoagulants: should they replace heparins and warfarin?

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20110101

• Electrophysiology and adult congenital heart disease: advances and options.

  Progress in cardiovascular diseases 20110101

• South African experts comment on FDA approval of dabigatran in atrial fibrillation.

  Cardiovascular journal of Africa 20110101

• Comparing the 2010 North American and European atrial fibrillation guidelines.

  The Canadian journal of cardiology 20110101

• Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.

  The Canadian journal of cardiology 20110101

• An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.

  Journal of medical economics 20110101

• Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.

  Cardiology in review 20110101

• New oral anticoagulants for venous thromboembolism prophylaxis in orthopaedic surgery.

  Instructional course lectures 20110101

• Stroke prevention in atrial fibrillation.

  Cardiovascular journal of Africa 20110101

• Stroke risk reduction: focus of the new ESC guidelines.

  Cardiovascular journal of Africa 20110101

• Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.

  Circulation journal : official journal of the Japanese Circulation Society 20110101

• Re-LY trial: new sub-analyses highlight stroke reduction in all types of non-valvular atrial fibrillation.

  Cardiovascular journal of Africa 20110101

• Stroke prevention in nonvalvular atrial fibrillation.

  Texas Heart Institute journal 20110101

• [Atrial fibrillation: novel possibilities of anticoagulant therapy in patients subjected to cardioversion].

  Kardiologiia 20110101

• Drug name alert: potential for confusion between pradax and plavix.

  Dynamics (Pembroke, Ont.) 20110101

• Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.

  Advances in surgery 20110101

• Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.

  BMJ (Clinical research ed.) 20110101

• Cost of dabigatran for atrial fibrillation.

  BMJ (Clinical research ed.) 20110101

• Dabigatran.

  AJNR. American journal of neuroradiology 20110101

• Wound problems following hip arthroplasty before and after the introduction of a direct thrombin inhibitor for thromboprophylaxis.

  Hip international : the journal of clinical and experimental research on hip pathology and therapy 20110101

• [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].

  Kardiologiia 20110101

• Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.

  Cerebrovascular diseases (Basel, Switzerland) 20110101

• Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs.

  Cerebrovascular diseases (Basel, Switzerland) 20110101

• Pharmacological basis and clinical evidence of dabigatran therapy.

  Journal of hematology & oncology 20110101

• Dabigatran emerges as safe and effective warfarin alternative. The recently approved drug is more expensive, but appears to be more predictable.

  Heart advisor 20110101

• Stroke in atrial fibrillation--hope on the horizon?

  Journal of the Royal Society, Interface 20101206

• [New oral anticoagulants: better than vitamin K antagonists?].

  Der Internist 20101201

• Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.

  Thrombosis and haemostasis 20101201

• First oral warfarin alternative approved in the US.

  Nature reviews. Drug discovery 20101201

• New synthetic antithrombotic agents for venous thromboembolism: pentasaccharides, direct thrombin inhibitors, direct Xa inhibitors.

  Clinics in chest medicine 20101201

• Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial.

  The Lancet. Neurology 20101201

• Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk.

  The Lancet. Neurology 20101201

• [Dabigatran induced exanthema].

  Revista clinica espanola 20101201

• Warfarin or not.

  The journal of the Royal College of Physicians of Edinburgh 20101201

• Advances in the treatment of atrial fibrillation.

  Minerva cardioangiologica 20101201

• Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation.

  Circulation 20101130

• Use of dabigatran etexilate to reduce breast cancer progression.

  Cancer biology & therapy 20101115

• Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.

  The Medical letter on drugs and therapeutics 20101115

• Dabigatran: the anticoagulant we have long expected?

  Recent patents on cardiovascular drug discovery 20101101

• Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.

  Circulation. Cardiovascular quality and outcomes 20101101

• Intracerebral hemorrhage: Pick your poison.

  Cleveland Clinic journal of medicine 20101101

• What's new in treating older adults?

  Cleveland Clinic journal of medicine 20101101

• [Novel anticoagulants for stroke prevention in atrial fibrillation].

  Deutsche medizinische Wochenschrift (1946) 20101101

• [Two new anticoagulants available in 2010--Dabigatran Etexilate and Rivaroxaban: expected progresses--raised problems].

  Annales pharmaceutiques francaises 20101101

• New options for stroke prevention in atrial fibrillation.

  The American journal of managed care 20101101

• Dabigatran v warfarin. Compare with higher standard.

  BMJ (Clinical research ed.) 20101026

• The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression.

  Thrombosis research 20101001

• Dabigatran offers the simplest solution for thromboprophylaxis after orthopaedic surgery in patients allergic to low-molecular-weight heparins.

  British journal of haematology 20101001

• Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

  Arteriosclerosis, thrombosis, and vascular biology 20101001

• Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

  Cardiovascular therapeutics 20101001

• Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.

  Acta cardiologica 20101001

• [Medication of the month. Dabigatran etixilate (Pradaxa): an oral anticoagulant acting as a direct selective inhibitor of thrombin].

  Revue medicale de Liege 20101001

• A new anticoagulant for a new era: review of recent data on dabigatran etexilate.

  Clinical advances in hematology & oncology : H&O 20101001

• Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

  Lancet (London, England) 20100918

• Quality of anticoagulation control in atrial fibrillation.

  Lancet (London, England) 20100918

• [Oral prevention of thromboembolism with rivaroxaban and dabigatran: are the newly approved drugs innovations in orthopaedic and trauma surgery? ].

  Zeitschrift fur Orthopadie und Unfallchirurgie 20100901

• Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.

  Thrombosis research 20100901

• Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.

  Thrombosis research 20100901

• Dabigatran acylglucuronide, the major human metabolite of dabigatran: in vitro formation, stability, and pharmacological activity.

  Drug metabolism and disposition: the biological fate of chemicals 20100901

• Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?

  The American journal of medicine 20100901

• In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.

  Thrombosis research 20100901

• [Advances in the prevention of cerebral ischaemia due to atrial fibrillation].

  Neurologia (Barcelona, Spain) 20100901

• Warfarin: is the end nigh? Please?

  The journal of the Royal College of Physicians of Edinburgh 20100901

• When a virtue becomes a problem. The new oral anticoagulants.

  Journal of thrombosis and haemostasis : JTH 20100801

• Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.

  Thrombosis and haemostasis 20100801

• Dabigatran may not be an effective anticoagulant for haemodialysis.

  Nephrology (Carlton, Vic.) 20100801

• Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs.

  Cerebrovascular diseases (Basel, Switzerland) 20100801

• New oral anticoagulant drugs in cardiovascular disease.

  Thrombosis and haemostasis 20100701

• Clot prevention--common questions about medications.

  Australian family physician 20100701

• Does dabigatran improve stroke prevention in atrial fibrillation? A rebuttal.

  Journal of thrombosis and haemostasis : JTH 20100601

• Will direct thrombin inhibition change the boundaries of oral anti-coagulation?

  QJM : monthly journal of the Association of Physicians 20100601

• Old versus new anticoagulants: focus on pharmacology.

  Recent patents on cardiovascular drug discovery 20100601

• Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

  Thrombosis and haemostasis 20100601

• Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation.

  Stroke 20100601

• Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.

  Expert opinion on pharmacotherapy 20100601

• Boehringer launches first direct thrombin inhibitor: dabigatran (Pradaxa).

  Cardiovascular journal of Africa 20100601

• Drug and dietary interactions of the new and emerging oral anticoagulants.

  International journal of clinical practice 20100601

• [New oral anticoagulants: prospects].

  La Revue du praticien 20100520

• New anticoagulants for prevention and treatment of venous thromboembolism.

  Current vascular pharmacology 20100501

• Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.

  Archives of orthopaedic and trauma surgery 20100501

• Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement.

  The Cochrane database of systematic reviews 20100414

• Dabigatran etexilate: a new thrombin inhibitor.

  The Medical journal of Australia 20100405

• Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.

  Journal of thrombosis and haemostasis : JTH 20100401

• Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

  Clinical pharmacokinetics 20100401

• Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).

  Expert opinion on pharmacotherapy 20100401

• Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.

  Croatian medical journal 20100401

• Dabigatran: ready for prime time?

  Polskie Archiwum Medycyny Wewnetrznej 20100401

• Potential of new anticoagulants in patients with cancer.

  Thrombosis research 20100401

• Dabigatran versus warfarin for venous thromboembolism.

  The New England journal of medicine 20100318

• Dabigatran versus warfarin for venous thromboembolism.

  The New England journal of medicine 20100318

• Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.

  Expert opinion on pharmacotherapy 20100301

• Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development.

  Thrombosis and haemostasis 20100301

• DVT: a new era in anticoagulant therapy.

  Arteriosclerosis, thrombosis, and vascular biology 20100301

• [Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].

  Deutsche medizinische Wochenschrift (1946) 20100301

• New oral anticoagulants: a practical guide for clinicians.

  Journal of thrombosis and thrombolysis 20100201

• Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?

  Current opinion in neurology 20100201

• Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.

  Thrombosis and haemostasis 20100201

• [Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?].

  Deutsche medizinische Wochenschrift (1946) 20100201

• [Current state and perspectives of pharmacological and non-pharmacological treatment of atrial fibrillation: overview].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100201

• The ultimate anticoagulants?

  Cardiovascular journal of Africa 20100201

• Atrial fibrillation: A promising new anticoagulant for stroke prevention.

  Nature reviews. Cardiology 20100101

• [Dabigatran in the treatment of a morbidly obese patient with recurring venous thrombosis].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20100101

• New oral anticoagulants in development: potential for improved safety profiles.

  Reviews in neurological diseases 20100101

• [Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study].

  Kardiologiia 20100101

• New options with dabigatran etexilate in anticoagulant therapy.

  Vascular health and risk management 20100101

• [Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].

  Khirurgiia 20100101

• Dabigatran and acute stroke thrombolysis.

  Cerebrovascular diseases (Basel, Switzerland) 20100101

• Dabigatran and stroke thrombolysis.

  Cerebrovascular diseases (Basel, Switzerland) 20100101

• [Anticoagulant therapy in cardiology: yesterday, today, tomorrow].

  Kardiologiia 20100101

• Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

  PharmacoEconomics 20100101

• New anticoagulants for the prevention of thromboembolism.

  Current pharmaceutical design 20100101

• Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management.

  Current pharmaceutical design 20100101

• Managing bleeding complications in patients treated with the old and the new anticoagulants.

  Current pharmaceutical design 20100101

• Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran.

  Cerebrovascular diseases (Basel, Switzerland) 20100101

• Focus on 2010 ESC Congress: new ESC guidelines and data on dabigatran.

  Cardiovascular journal of Africa 20100101

• Warfarin versus new agents: interpreting the data.

  Hematology. American Society of Hematology. Education Program 20100101

• Dabigatran versus warfarin in patients with atrial fibrillation.

  The New England journal of medicine 20091231

• Dabigatran versus warfarin in patients with atrial fibrillation.

  The New England journal of medicine 20091231

• Dabigatran versus warfarin in patients with atrial fibrillation.

  The New England journal of medicine 20091231

• Dabigatran versus warfarin in patients with atrial fibrillation.

  The New England journal of medicine 20091231

• Dabigatran versus warfarin in patients with atrial fibrillation.

  The New England journal of medicine 20091231

• Dabigatran versus warfarin in patients with atrial fibrillation.

  The New England journal of medicine 20091231

• Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

  The New England journal of medicine 20091210

• [New oral anticoagulants. Consequences for perioperative coagulation diagnostics and therapy].

  Der Anaesthesist 20091201

• At last, a RE-LYable alternative to warfarin for atrial fibrillation.

  International journal of stroke : official journal of the International Stroke Society 20091201

• Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?

  Discovery medicine 20091201

• Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts.

  Arthritis and rheumatism 20091101

• [New drug in atrial fibrillation--how does it function in regular health care?].

  Lakartidningen 20091101

• [The results of the RE-lY study promise more effective, safer and easier prevention of embolic complications in patients with non-valvular atrial fibrillation].

  Vnitrni lekarstvi 20091101

• [Pregnancy and venous thromboembolism. North-American and European guidelines. American College of Chest Physicians].

  Journal des maladies vasculaires 20091101

• New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.

  ANZ journal of surgery 20091101

• New anticoagulants and regional anesthesia.

  Current opinion in anaesthesiology 20091001

• Anticoagulation with {blacktriangledown}dabigatran or{blacktriangledown}rivaroxaban.

  Drug and therapeutics bulletin 20091001

• Dabigatran etexilate in venous thromboembolism.

  Drugs of today (Barcelona, Spain : 1998) 20091001

• Can we rely on RE-LY?

  The New England journal of medicine 20090917

• Dabigatran versus warfarin in patients with atrial fibrillation.

  The New England journal of medicine 20090917

• [Stroke prevention in atrial fibrillation. Marcumar alternative in sight].

  MMW Fortschritte der Medizin 20090917

• A logical approach to surgical thromboprophylaxis.

  Current opinion in hematology 20090901

• Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

  Health technology assessment (Winchester, England) 20090901

• [Dabigatran (Pradaxa): efficacy and safety].

  Annales francaises d'anesthesie et de reanimation 20090901

• [Dabigatran: clinical pharmacology].

  Annales francaises d'anesthesie et de reanimation 20090901

• Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits.

  Journal of thrombosis and haemostasis : JTH 20090801

• What can ongoing clinical trials of anticoagulants demonstrate?

  Journal of cardiovascular medicine (Hagerstown, Md.) 20090801

• New anticoagulants for atrial fibrillation.

  Seminars in thrombosis and hemostasis 20090701

• [New agents for the prevention of venous thromboembolism].

  Der Internist 20090601

• Dabigatran: new drug. Continue to use heparin, a better-known option.

  Prescrire international 20090601

• Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.

  American heart journal 20090501

• [The new oral anticoagulant in the Netherlands].

  Nederlands tijdschrift voor geneeskunde 20090418

• [New anticoagulants].

  Deutsche medizinische Wochenschrift (1946) 20090401

• Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?

  Archives of cardiovascular diseases 20090401

• The novel anticoagulants: entering a new era.

  Swiss medical weekly 20090207

• Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.

  The Journal of arthroplasty 20090101

• Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development.

  Clinical pharmacokinetics 20090101

• Dabigatran etexilate for prevention of venous thromboembolism.

  Thrombosis and haemostasis 20090101

• Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.

  Thrombosis and haemostasis 20090101

• Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• In the pipeline: new oral anticoagulants for the prevention of venous thromboembolism.

  Orthopedics 20090101

• Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

  Clinical therapeutics 20090101

• New oral anticoagulants: not quite there yet.

  Polskie Archiwum Medycyny Wewnetrznej 20090101

• Dabigatran etexilate: future directions in anticoagulant treatment.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101

• Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101

• Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101

• Oral antithrombotic inhibitors: dabigatran etexilate, meeting an unmet need?

  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 20090101

• [Dabigatran and rivaroxaban, new oral anticoagulants for the treatment of venous thromboembolism].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• [Pharmacokinetics and pharmacodynamics of the new oral anticoagulants dabigatran and rivaroxaban].

  Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101

• [From old to new anticoagulants: the role of the biologist].

  Annales de biologie clinique 20090101

• New anticoagulants for the prevention of deep venous thrombosis: time to consider cost effectiveness?

  PharmacoEconomics 20090101

• A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.

  PharmacoEconomics 20090101

• [Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement].

  Therapie 20090101

• [Dabigatran versus Warfarin in patients with atrial fibrillation. Results of the RE-LY study].

  Kardiologiia 20090101

• Dabigatran: safer, more effective and easier to use than warfarin.

  Cardiovascular journal of Africa 20090101

• Prevention and treatment of thromboembolic events in medical patients and new anticoagulants.

  Acta clinica Belgica 20090101

• [Thrombin inhibitor shows stable safety profile in the practice].

  MMW Fortschritte der Medizin 20081211

• Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.

  Journal of clinical pharmacology 20081201

• Emergence of new oral antithrombotics: a critical appraisal of their clinical potential.

  Vascular health and risk management 20081201

• Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.

  Pharmacotherapy 20081101

• [Anaesthesia and thromboembolic disease].

  Medicina clinica 20081101

• [New oral anticoagulants: molecular characteristics, mechanisms of action, pharmacokinetics and pharmacodynamics].

  Medicina clinica 20081101

• New therapeutic option for thromboembolism--dabigatran etexilate.

  Expert opinion on pharmacotherapy 20081001

• [Anticoagulation in atrial fibrillation].

  Hamostaseologie 20081001

• [Always more amputations in Germany?].

  Deutsche medizinische Wochenschrift (1946) 20081001

• Preventing venous thromboembolism through risk assessment approaches.

  British journal of nursing (Mark Allen Publishing) 20080601

• New anticoagulant agents: direct thrombin inhibitors.

  Cardiology clinics 20080501

• Prevention of venous thromboembolism in the geriatric patient.

  Cardiology clinics 20080501

• New anticoagulants for treatment of venous thromboembolism.

  Arteriosclerosis, thrombosis, and vascular biology 20080301

• The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20080201

• Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.

  Seminars in thrombosis and hemostasis 20080201

• [Update in hospital internal medicine (2007): a selection].

  Revue medicale suisse 20080130

• Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects.

  Clinical pharmacokinetics 20080101

• Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.

  Clinical pharmacokinetics 20080101

• Dabigatran etexilate.

  Drugs 20080101

• The top 4 advances in antithrombotic care in the last year.

  Thrombosis research 20080101

• Brave new world: the current and future use of novel anticoagulants.

  Thrombosis research 20080101

• New issues in oral anticoagulants.

  Hematology. American Society of Hematology. Education Program 20080101

• Dabigatran versus enoxaparin after total hip replacement.

  Lancet (London, England) 20071215

• Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.

  Journal of thrombosis and haemostasis : JTH 20071101

• Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).

  The American journal of cardiology 20071101

• Trials of venous thromboembolism prevention.

  Lancet (London, England) 20070915

• Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.

  Lancet (London, England) 20070915

• The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.

  British journal of clinical pharmacology 20070901

• Development of oral anticoagulants.

  British journal of clinical pharmacology 20070901

• Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke.

  Current opinion in investigational drugs (London, England : 2000) 20070901

• The new anticoagulants.

  Perspectives in vascular surgery and endovascular therapy 20070901

• Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.

  Thrombosis and haemostasis 20070801

• Beyond unfractionated heparin and warfarin: current and future advances.

  Circulation 20070731

• In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.

  Thrombosis and haemostasis 20070701

• Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis.

  Journal of thrombosis and haemostasis : JTH 20070601

• Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery.

  Journal of clinical pharmacology 20070301

• New anticoagulants: from bench to bedside.

  Hamostaseologie 20070201

• Agents to control bleeding show promise.

  JAMA 20070124

• Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis.

  British journal of clinical pharmacology 20061101

• Direct thrombin inhibitors.

  The New England journal of medicine 20050908

• New anticoagulants.

  Journal of thrombosis and haemostasis : JTH 20050801

• Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement.

  Journal of clinical pharmacology 20050501

• A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

  Journal of thrombosis and haemostasis : JTH 20050101

• Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I.

  Journal of thrombosis and haemostasis : JTH 20040901

• Oral direct thrombin inhibitors in clinical development.

  Journal of internal medicine 20031001

• Structure-based design of novel potent nonpeptide thrombin inhibitors.

  Journal of medicinal chemistry 20020425